Cargando…

Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre

BACKGROUND: Myasthenia gravis is an autoimmune disease mediated by antibodies against proteins associated with the postsynaptic membrane of the neuromuscular junction. Several drugs may trigger an exacerbation of the disease. Melatonin supplements are widely used for the treatment of insomnia as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nedkova-Hristova, Velina, Vélez-Santamaría, Valentina, Casasnovas, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640643/
https://www.ncbi.nlm.nih.gov/pubmed/33148186
http://dx.doi.org/10.1186/s12883-020-01975-y
_version_ 1783605789428023296
author Nedkova-Hristova, Velina
Vélez-Santamaría, Valentina
Casasnovas, Carlos
author_facet Nedkova-Hristova, Velina
Vélez-Santamaría, Valentina
Casasnovas, Carlos
author_sort Nedkova-Hristova, Velina
collection PubMed
description BACKGROUND: Myasthenia gravis is an autoimmune disease mediated by antibodies against proteins associated with the postsynaptic membrane of the neuromuscular junction. Several drugs may trigger an exacerbation of the disease. Melatonin supplements are widely used for the treatment of insomnia as they are well tolerated with few side effects. The role of melatonin in the immune system and its effects in autoimmune disorders remain uncertain. CASE PRESENTATION: We identified three patients in our referral centre from 2014 to 2019 who presented a worsening within days or weeks of starting melatonin. Two of them stopped the treatment without clinical improvement in the next week. Increasing dose of corticosteroids did not lead to clinical improvement in the next month and one of the patients was finally administered intravenous immunoglobulins. CONCLUSION: Melatonin may trigger exacerbations of myasthenia gravis, probably due to an upregulation of the adaptive immune system and an interaction with the corticosteroids and other immunosuppressant treatments. We consider that melatonin should be administered with caution in these patients.
format Online
Article
Text
id pubmed-7640643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76406432020-11-04 Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre Nedkova-Hristova, Velina Vélez-Santamaría, Valentina Casasnovas, Carlos BMC Neurol Case Report BACKGROUND: Myasthenia gravis is an autoimmune disease mediated by antibodies against proteins associated with the postsynaptic membrane of the neuromuscular junction. Several drugs may trigger an exacerbation of the disease. Melatonin supplements are widely used for the treatment of insomnia as they are well tolerated with few side effects. The role of melatonin in the immune system and its effects in autoimmune disorders remain uncertain. CASE PRESENTATION: We identified three patients in our referral centre from 2014 to 2019 who presented a worsening within days or weeks of starting melatonin. Two of them stopped the treatment without clinical improvement in the next week. Increasing dose of corticosteroids did not lead to clinical improvement in the next month and one of the patients was finally administered intravenous immunoglobulins. CONCLUSION: Melatonin may trigger exacerbations of myasthenia gravis, probably due to an upregulation of the adaptive immune system and an interaction with the corticosteroids and other immunosuppressant treatments. We consider that melatonin should be administered with caution in these patients. BioMed Central 2020-11-04 /pmc/articles/PMC7640643/ /pubmed/33148186 http://dx.doi.org/10.1186/s12883-020-01975-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Nedkova-Hristova, Velina
Vélez-Santamaría, Valentina
Casasnovas, Carlos
Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title_full Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title_fullStr Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title_full_unstemmed Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title_short Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
title_sort myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640643/
https://www.ncbi.nlm.nih.gov/pubmed/33148186
http://dx.doi.org/10.1186/s12883-020-01975-y
work_keys_str_mv AT nedkovahristovavelina myastheniagravisexacerbationaftermelatoninadministrationcaseseriesfromatertiaryreferralcentre
AT velezsantamariavalentina myastheniagravisexacerbationaftermelatoninadministrationcaseseriesfromatertiaryreferralcentre
AT casasnovascarlos myastheniagravisexacerbationaftermelatoninadministrationcaseseriesfromatertiaryreferralcentre